$127.11
1.16% yesterday
Nasdaq, Nov 25, 10:02 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock price

$127.11
+11.03 9.50% 1M
-12.29 8.82% 6M
-4.65 3.53% YTD
+14.09 12.47% 1Y
+39.25 44.67% 3Y
+12.13 10.55% 5Y
+107.66 553.52% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+1.46 1.16%
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Key metrics

Market capitalization $12.87b
Enterprise Value $11.93b
P/E (TTM) P/E ratio 34.05
EV/FCF (TTM) EV/FCF 27.10
EV/Sales (TTM) EV/Sales 5.32
P/S ratio (TTM) P/S ratio 5.74
P/B ratio (TTM) P/B ratio 4.73
Revenue growth (TTM) Revenue growth 25.72%
Revenue (TTM) Revenue $2.24b
EBIT (operating result TTM) EBIT $588.30m
Free Cash Flow (TTM) Free Cash Flow $440.10m
Cash position $1.23b
EPS (TTM) EPS $3.73
P/E forward 29.77
P/S forward 5.46
EV/Sales forward 5.06
Short interest 2.87%
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

25x Buy
86%
4x Hold
14%

Analyst Opinions

29 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,243 2,243
26% 26%
100%
- Direct Costs 55 55
1% 1%
2%
2,187 2,187
27% 27%
98%
- Selling and Administrative Expenses 913 913
10% 10%
41%
- Research and Development Expense 661 661
25% 25%
29%
614 614
66% 66%
27%
- Depreciation and Amortization 26 26
29% 29%
1%
EBIT (Operating Income) EBIT 588 588
68% 68%
26%
Net Profit 386 386
102% 102%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Neutral
Investors Business Daily
4 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positive
Seeking Alpha
18 days ago
Neurocrine Biosciences, Inc.'s August share price decline after the messy phase 2 results of NBI-568 in schizophrenia patients is understandable, but the magnitude is not. Neurocrine is trading at slow growth big pharma multiples, not at multiples of a company with significant growth potential that it is. Ingrezza continues to deliver strong growth and cash flows for the company, and crinecerfo...
Neutral
PRNewsWire
19 days ago
Data Support Positive Impact of INGREZZA in People With Huntington's Disease Chorea Findings Presented at the 2024 Annual Meeting of the Huntington Study Group SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented subgroup analyses and data from the KINECT®-HD study showing the impact of INGREZZA® (valbenazine) capsules on emotional health and psyc...
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kyle Gano
Employees 1,400
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today